Sun Galaxy Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 13 Year, 1 Month
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 1.50 M
About Sun Galaxy Pharmaceuticals
Sun Galaxy Pharmaceuticals Private Limited (SGPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 January 2012 and has a history of 13 years and one month. Its registered office is in Delhi, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.50 M.
Amit Garg and Sanjay Garg serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33110DL2012PTC230145
- Company No.
230145
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jan 2012
- Date of AGM
30 Sep 2015
- Date of Balance Sheet
31 Mar 2015
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Sun Galaxy Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Garg  | Director | 17-Jan-2012 | Current |
| Sanjay Garg | Director | 20-Oct-2014 | Current |
Financial Performance of Sun Galaxy Pharmaceuticals.
Enhance accessibility to Sun Galaxy Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Sun Galaxy Pharmaceuticals?
In 2015, Sun Galaxy Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Scholarbeam Publications Private LimitedAmit Garg is a mutual person
- Scholarbeam Education Private Limited
Amit Garg is a mutual person
- Sharmistha Publications Private Limited
Amit Garg is a mutual person
Charges (Loans)
₹1.50 M
₹0
Charges Breakdown by Lending Institutions
- Syndicate Bank : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Mar 2013 | Syndicate Bank | ₹1.50 M | Open |
How Many Employees Work at Sun Galaxy Pharmaceuticals?
Unlock and access historical data on people associated with Sun Galaxy Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sun Galaxy Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sun Galaxy Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
